Comparison of allergy prevalence between brimonidine/timolol fixed combination and 0.15% brimonidine in glaucoma patientsopen access녹내장에서 브리모니딘/티몰롤 복합제제와 0.15% 브리모니딘 사용 시 알레르기 발생률의 비교
- Authors
- Park, Eun Jung; Chun, Yeoun Sook
- Issue Date
- May-2018
- Publisher
- Korean Ophthalmological Society (KOS)
- Keywords
- 0.15% brimonidine; 0.2% brimonidine/0.5% timolol fixed combination; Glaucoma; Korean; Ocular allergy
- Citation
- Journal of Korean Ophthalmological Society, v.59, no.5, pp 451 - 458
- Pages
- 8
- Journal Title
- Journal of Korean Ophthalmological Society
- Volume
- 59
- Number
- 5
- Start Page
- 451
- End Page
- 458
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3193
- DOI
- 10.3341/jkos.2018.59.5.451
- ISSN
- 0378-6471
2092-9374
- Abstract
- Purpose: To compare the allergy prevalence and clinical manifestations of 0.2% brimonidine/0.5% timolol fixed combination (BTFC) and 0.15% brimonidine in Korean patients with glaucoma. Methods: We retrospectively analyzed the medical records of 196 glaucoma patients treated with BTFC and 234 glaucoma patients treated with 0.15% brimonidine. We compared sex, age, type of glaucoma, treatment period, allergy history, onset time of ocular allergy and clinical characteristics of allergy in the two groups. Results: Ocular allergy percentages 10.14% in the BTFC group and 22.02% in the 0.15% brimonidine group, and the risk of allergy was approximately 0.4 times lower in patients using BTFC (hazard ratio = 2.5, p = 0.009). The BTFC group developed ocular allergy at a mean of 20.5 months (range: 1.7–51.1 months), and the 0.15% brimonidine group developed ocular allergy at a mean of 7.7 months (range: 0.4–50.8 months). In the BTFC group, 50% of the ocular allergy occurred within 15 months, and within 5 months in the 0.15% brimonidine group. Clinical characteristics of brimonidine allergy involved two types of conjunctival follicles and conjunctival papillae, but there were no significant differences in incidence according to allergy type (p = 0.566). Conclusions: The prevalence of ocular allergy in the BTFC group was lower than that in the 0.15% brimonidine group in Korean patients with glaucoma. The results of this study are expected to be useful for patient education and compliance improvement using brimonidine. © 2018 The Korean Ophthalmological Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3193)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.